glp 1 drugs india Press Release Page India Tightens GLP-1 Weight Loss

Wang S, Wang S, Wang Y, Luan J

Without medical oversight, patients are more likely to miss key labs, struggle with side effects, or stop treatment early due to avoidable issues like incorrect dosing or lack of support

Cotter DG, Schugar RC, Crawford PA

A randomized, phase 3, open-label trial comparing the effect of the addition of tirzepatide once weekly versus insulin lispro (U100) three times daily in participants with type 2 diabetes inadequately controlled on insulin glargine (U100) with or without metformin (SURPASS-6)

Overall the trials established that liraglutide together with diet and exercise maintained weight loss and induced further weight loss over 56 weeks

Bhatti JA, Nathens AB, Thiruchelvam D, Grantcharov T, Goldstein BI, Redelmeier DA